BRCAness digitalMLPA profiling predicts benefit of intensified platinum-based chemotherapy in triple-negative and luminal-type breast cancer.
Esther H LipsAnne Benard-SlagterMark OpdamCaroline E ScheermanJelle WesselingFrans B L HogervorstSabine C LinnSuvi SavolaPetra M NederlofPublished in: Breast cancer research : BCR (2020)
The digitalMLPA is a reliable method to detect a BRCA1- and BRCA2-like pattern on clinical samples and predicts platinum-based chemotherapy benefit in both triple-negative and luminal-type BC.